Biocon Share Price in Focus; Net Profit Surges 475% in Q3 FY26 Results

Biocon Limited announced its consolidated financial results for the quarter ended December 31, 2025.

Consolidated revenue for the quarter stood at ₹4,290 crore, marking an 11% year-on-year increase. Operating revenue rose 9% YoY to ₹4,173 crore, reflecting consistent business momentum. EBITDA for the quarter reached ₹951 crore, up 21% YoY, while EBITDA margin expanded to 22%, demonstrating improved operating efficiency.

Profit before tax, excluding exceptional items, rose sharply by 64% to ₹226 crore. Reported net profit jumped significantly to ₹144 crore, recording a strong 475% growth compared to the previous year’s quarter.

Core EBITDA and R&D Investments

Core EBITDA for the quarter reached ₹1,221 crore, growing 21% year-on-year, with core EBITDA margin improving to 29%. This reflects better cost control and operational performance across segments.

Investment in research and development remained strong, with net R&D spending at ₹249 crore, accounting for 8% of revenue excluding Syngene operations. Continued investment highlights the company’s focus on strengthening future product pipelines and innovation capabilities.

Segment-wise Revenue Performance

The biosimilars business under Biocon Biologics continued to drive performance, reporting revenue of ₹2,497 crore, up 9% YoY, supported by global demand and portfolio expansion.

The generics business, including APIs and formulations, recorded strong growth of 24% YoY with revenue reaching ₹851 crore.

Meanwhile, the CRDMO segment led by Syngene reported revenue of ₹917 crore, reflecting a marginal 3% decline compared to last year, impacted by client spending adjustments.

Biocon Share Price Performance

On February 13, 2026, Biocon share price (NSE: BIOCON) opened at ₹374.00, touching the day’s high at ₹381.30, as of 9:59 AM on the NSE.

Also Read: Biocon Raises Stake in Biocon Biologics to 98%!

Conclusion

Biocon’s Q3 FY26 results demonstrate improving margins, steady revenue growth, and a significant rebound in profitability. Strong performance in biosimilars and generics, along with continued R&D investments, positions the company well for sustained growth despite minor softness in contract research services.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.